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SPECIAL NOTE
The information provided in this report represents the latest 
data reported to the Poliomyelitis Surveillance Unit from State Health 
Departments, Epidemic Intelligence Service Officers, participating 
laboratories, and other pertinent sources. Much of the material is 
preliminary in nature and is subject to confirmation and change. It 
is distributed for the benefit of all participants with the -understand­
ing that it will not be released to the press or to unauthorized per­
sons. State Health Officers, of course, are free to reveal any infor­
mation they may wish concerning data from their State.
Dr. Howard J. Shaugnessy, Director, Laboratory Division, Illinois 
Department of Public Health reports isolation of type 1 poliomyelitis 
virus from the stool of PSU case number 111-1 (See PSU Report No. l).
Yesterday the isolation of the same type of virus from a Cali­
fornia case was reported by Dr. Edwin H. Lennette. Both cases received 
Cutter Vaccine.
Today four accepted cases were added to the cumulative list, giving 
a total of 33, as of 7:30 P.M., May 3, 1955. Three of todayTs cases were
CHerokee 7520 
ATwood 2791 
CRescent 9207 
DEarborn 0482
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reported from Oregon, and all received Cutter Vaccine. Two of these 
cases developed paralysis, and in one the initial site of paralysis was 
the arm inoculated.
There is a single case reported from Indiana. Paralysis first 
developed in the left arm nine days following inoculation in the left 
shoulder with Lilly Vaccine. This is the fourth case reported in associa­
tion with Lilly Vaccine but the first one with any cox-relation between 
site of inoculation and site of first paralysis.
TodayTs totals can be broken down as follows:
bZ_tH3e: paralytic 30
non-paralytic 3
by manufacturers: Cutter 29
Lilly 4
by State: California 14
Idaho 9
Oregon 3
Washington 1
Colorado 1
Illinois 1
Indiana 1
Louisiana 2
Georgia 1
Investigation on suspect cases is proceeding in California, Idaho, 
Colorado, Illinois, Louisiana, Michigan, Missouri, Nevada, Ohio, and West 
Virginia.
The news release enclosed as attachment No. 1 to the present report 
restates the immediate questions of national importance in the polio situa­
tion. The data as PSU receives it, is transmitted immediately to the 
advisory group of experts in Washington. As this document makes clear,
PSU data are already in use.
In order to amplify the scheme for collection of data outlined in 
PSU Report No. 1, a recommendation for collection and transmission of in­
formation is outlined in attachment No. 2. A proposed Poliomyelitis 
Investigation Form is also included.
sM L N a 'i W t\ k \ c nT
Neal Nathanson, M.D., Chief
Poliomyelitis Surveillance Unit
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Accepted Cases Associated with Poliomyelitis Vaccine
Daily Cumulative Summary
PSU
Case No Residence
Init­
ials Age Sex
Date
Inoc.
Ind-1 North Vernon WC 7 M 4-20
Ore-1 Portland KK 4 M 4-20
Ore-2 Portland SJ 11 F 4-15
Ore-3 Portland EH 4 F 4-20
Code of Abbreviations:
PSU - Poliomyelitis Surveillance Unit 
Mfr - Manufacturer
C - Cutter Laboratories 
L - Lilly Laboratories
LA - Left Arm LL - Left Leg or Buttocks
Date Date 
1st 1st 
Symp Para
Site
Inoc
Site
1st
Para Mfr
Lot
No
NEW CASES
Indiana
4-27 4-29 LA Arms L 649335?
Oregon
4-27 4-30 LA LA C E5972
4-29 4-29 LA Legs C E5972
4-29 None LA None C E5972
RA - Right Arm RL - Right Leg or Buttocks
Remarks
Non-paralytic
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Attachment No. 1 to
Poliomyelitis Surveillance Report No. 3
"THE FOLLOWING NEWS RELEASE WAS ISSUED BY THE DEPARTMENT OF HEALTH, 
EDUCATION, AND WELFARE AT 6:00 P.M. SATURDAY AND IS BEING SENT TO ALL 
STATE HEALTH OFFICERS AND REGIONAL MEDICAL DIRECTORS OF THE PUBLIC HEALTH 
SERVICE. REGIONAL MEDICAL DIRECTORS ARE URGED ALSO TO CONTACT STATE HEALTH 
OFFICERS IN THEIR REGIONS MONDAY MORNING AS SOON AS POSSIBLE TO BE SURE IT 
HAS REACHED THEM. AN ADDITIONAL TELEGRAPHING WILL BE MADE BY GOVERNMENT 
TELETYPE TO REGIONAL MEDICAL DIRECTORS MONDAY MORNING TO BE SURE THEY RE­
CEIVE IT.
"THE PUBLIC HEALTH SERVICE, U.S. DEPARTMENT OF HEALTH,EDUCATION,
AND WELFARE, MADE PUBLIC LATE TODAY A SUMMARY OF CONCLUSIONS AND RECOMMEN­
DATIONS OF AN ADVISORY GROUP OF EXPERTS IN THE FIELDS OF POLIOMYELITIS 
AND IMMUNOLOGY WHICH HAS JUST CONCLUDED A TWO-DAY MEETING AT THE NATIONAL 
INSTITUTES OF HEALTH IN BETHESDA, MARYLAND. THE MEETING WAS CALLED BY 
SURGEON GENERAL LEONARD A. SCHEELE TO ADVISE ON AN INVESTIGATION OF THE 
POLIOMYELITIS VACCINE PRODUCED BY THE CUTTER LABORATORIES OF BERKELEY, 
CALIFORNIA, WHICH WAS WITHDRAWN FROM DISTRIBUTION THIS WEEK.
"IN ADDITION TO THE CONSULTING GROUP AND STAFF MEMBERS OF THE 
PUBLIC HEALTH SERVICE TODAYfS MEETING INCLUDED TECHNICAL REPRESENTATIVES 
OF THE SIX PHARMACEUTICAL HOUSES MANUFACTURING THE VACCINE. DR. SCHEELE 
SAID THEY WERE INCLUDED SO THAT THE SERVICE MIGHT BENEFIT FROM THEIR 
SPECIAL KNOWLEDGE REGARDING THE PRODUCTION AND DISTRIBUTION OF VACCINE.
"IN ARRIVING AT CONCLUSIONS AND RECOMMENDATIONS THE GROUP WAS 
GUIDED BY LAST-MINUTE DATA OBTAINED BY TELEPHONE FROM HEALTH OFFICIALS 
IN VARIOUS PARTS OF THE COUNTRY CONCERNING CASES OF PARALYTIC POLIO OCCUR­
RING AMONG CHILDREN WHO HAD BEEN VACCINATED.
"AS OF NOON SATURDAY THE NUMBER OF CASES REPORTED TO THE PUBLIC 
HEALTH SERVICE WAS AS FOLLOWS: CALIFORNIA 16; IDAHO 8; LOUISIANA 2;
ILLINOIS 1; COLORADO 1; AND GEORGIA 1. THE VACCINE MANUFACTURED BY THE 
CUTTER LABORATORIES HAD BEEN USED IN ALL BUT THREE OF THESE CASES.
"IN RELEASING THE LATEST TABULATION THE SURGEON GENERAL POINTED OUT 
THAT AS OF THE PRESENT MOMENT THEY REPRESENTED A TOTAL OF ONLY 29 CASES. 
APPROXIMATELY A MILLION CHILDREN HAVE BEEN VACCINATED.
"IT IS IMPORTANT TO REMEMBER," DR. SCHEELE SAID, "THAT THE FIELD 
TRIALS OF THE VACCINE INDICATED THAT IT WAS FROM 60 TO 90 PERCENT EFFEC­
TIVE. IT MUST BE ANTICIPATED THAT ADDITIONAL CASES WILL INEVITABLY OCCUR 
AMONG SOME OF THOSE FOR WHOM THE VACCINE IS NOT EFFECTIVE."
"THE SURGEON GENERAL REITERATED THE BELIEF OF THE SERVICE THAT THE 
MASS INOCULATIONS NOW UNDERWAY SHOULD BE CONTINUED.
"IT WAS EMPHASIZED IN THE GROUPS* REPORT THAT AT THE PRESENT TIME 
THERE IS NO REASON TO SUGGEST THAT VACCINES OF MANUFACTURERS OTHER THAN 
CUTTER SHOULD BE WITHHELD. VACCINATIONS SHOULD BE CONTINUED.
"A SUMMARY OF THE RECOMMENDATIONS FOLLOWS:
"THE CONSULTANTS AGREED THAT THE DATA PRESENTED ON REPORTED CASES 
OF PARALYSIS FOLLOWING INJECTION WITH POLIOMYELITIS VACCINE MANUFACTURED 
BY THE CUTTER LABORATORIES JUSTIFY THE ACTION BY THE PUBLIC HEALTH SERVICE 
IN DISCONTINUING THE USE OF CUTTER VACCINE PENDING NECESSARY INVESTIGATION.
"THE GROUP SAID THAT THE FAILURE OF A SIGNIFICANT NUMBER OF CASES 
TO OCCUR FOLLOWING THE ADMINISTRATION OF VACCINE PREPARED BY MANUFACTURERS 
OTHER THAN CUTTER WARRANTS THE CONTINUATION OF VACCINATION WITH PRODUCTS 
PREPARED BY OTHER MANUFACTURERS.
"THE GROUPS* DISCUSSION OF THE CUTTER VACCINE CENTERED AROUND THREE 
BASIS QUESTIONS UPON WHICH CONTINUING STUDIES WERE RECOMMENDED:
(1) IS THE APPEARANCE OF POLIOMYELITIS AMONG PEOPLE INOCULATED 
WITH THE CUTTER VACCINE MERELY COINCIDENTAL?
(2) COULD THE INJECTION OF THE VACCINE HAVE PROVOKED THE APPEAR­
ANCE OF PARALYSIS IN A MANNER SIMILAR TO THE PROVOCATIVE EFFECT WHICH 
HAS BEEN OBSERVED AFTER THE USE OF OTHER IMMUNIZING AGENTS?
(3) WAS A LIVE VIRUS INTRODUCED BY THE INJECTION OF VACCINE?
"THE CONSULTANT GROUP AGREED THAT THE INCIDENCE AND DISTRIBUTION 
OF POLIOMYELITIS IN THE NEXT SEVERAL WEEKS WOULD SHED LIGHT ON THESE 
QUESTIONS.
’THE GROUP RECOMMENDED THAT EVERY EFFORT BE EXERTED TO STAY ABREAST 
ON A DAY TO DAY BASIS, OF THE CURRENT INCIDENCE OF POLIO AMONG THOSE WHO 
HAVE RECEIVED VACCINE - SECURING BOTH MEDICAL ANT) LABORATORY DATA ON EACH 
CASE REPORTED.
"IN ADDITION THE GROUP FELT THAT IT IS PARTICULARLY IMPORTANT THAT 
PRACTICING PHYSICIANS THEMSELVES SHOULD KEEP CAREFUL DATA ON ALL INOCULA­
TIONS THEY ADMINISTER, INCLUDING THE MANUFACTURER’S NAME, LOT NUMBER, SITE 
OF INOCULATION, AND GENERAL HEALTH OF THE INDIVIDUAL AND THAT THESE DATA 
BE REPORTED TO HEALTH DEPARTMENTS.
"IN ADDITION TO OBTAINING EPIDEMIOLOGICAL AND PHYSICAL DATA THE 
GROUP RECOMMENDED THAT CAREFUL LABORATORY STUDIES BE CONDUCTED ON AFFECTED 
INDIVIDUALS WHO HAVE BEEN INJECTED WITH THE VACCINE AND THEIR FAMILIES.
THE GROUP RECOGNIZED THAT THIS WILL MEAN A SEVERE STRAIN ON THE LABORATORY 
FACILITIES OF THE PUBLIC HEALTH SERVICE AND SUGGESTED THAT THE SURGEON 
GENERAL INVESTIGATE THE POSSIBILITY OF ENLISTING OTHER LABORATORY RESOURCES. 
THE GROUP AGREED TO SERVE ON A CONTINUING BARIS TO ADVISE THE SURGEON 
GENERAL AS NECESSARY."
OTIS L. ANDERSON, CHIEF 
BUREAU OF STATE SERVICES
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Recommended procedures for Report of Cases 
to PSU by State Polio Reporting Offices
The following priorities are recommended for the reporting of information 
on poliomyelitis cases to the PSU.
FIRST PRIORETY
Cases associated with Polio Vaccine
Send by teletype or telegraph collect the following minimum essential data: 
Residence, initials, age, sex, date inoculation, date first symptoms, date first 
Paralysis, site of inoculation, site of first paralysis, extent of paralysis, 
Manufacturer and lot number, specimens collected and laboratoiy to which submitted, 
and a brief summary about polio prevalence in general area for the previous 2 
weeks. Officer should specify whether he has accepted case as verified polio­
myelitis or is holding it as suspect pending further investigation. On all 
suspect cases subsequent reports at l*8-hour intervals or less should be sent by 
teletype or telegraph collect until final classification is determined.
(Note: Copies of today's report sent to State Polio Reporting
Officers include as Attachment No. it a map of locations where 
Government teletype is available. All State Public Health 
officials are authorized to use these facilities to transmit 
information to PSU. Information can be forwarded to teletype 
offices by phone or wire. Offices are listed in local directories 
under U. S. Government, General Services Administration.)
SECOND PRIORITY
£gses not associated with Polio Vaccine
Send weekly summary list preferably each Friday by air mail of all 
Verified cases, both paralytic and non-paralytic, giving as much of the following 
^formation as possible: Residence, initials, age, sex, date first symptoms,
^ate first paralysis, site first paralysis, extent of paralysis, specimens 
CQllected and laboratory to which submitted.
- 2 -
FORMS
The proposed form for collecting the significant data on all cases of 
polio mentioned in PSU Report No. 1 is now available for distribution. A copy 
is included with this report as Attachment No. 3. A small supply is being 
sent under separate cover to each Polio Reporting Officer and to the EIS 
Officers participating. Additional forms will be sent air mail on request.
These forms will be used routinely by the EIS Officers who will complete 
them in duplicate, submitting both copies to the State Reporting Officer, who 
should forward one to PSU when the essential clinical and epidemiological 
data have been obtained. It is hoped that this form will also be used when 
completed reports on cases not investigated by EIS Officers are submitted to 
PSU. In this way it will be possible to obtain the uniform data required for 
analysis.
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POLIOM YELITIS SURVEILLANCE FORM
State_
County
City or
Town______________________________
Date of Telephone
1. Name of Patient________________________________________________________2. Sex______ 3. Age________ 4. Birth____________5. Race___________ 6. No.______
Last First Middle
Residence
7. Address_______________________________________________________________  8. School_____________________________________ 9. Grade______________________
Date Onset Site of First
10. Date Patient First Felt Unwell___________________ Paralysis____________________________  Paralysis ___________________________________________________
11. Description of Illness;
Yes No Yes No
Fever Sore Throat
Headache Vomiting
Stiff Neck Diarrhea
Stiff Back Constipation
Back Pain Muscular Pain
13. Spinal Fluid: Yes___ No Cells______ Protein__________ 14.
12. Extent of Paralysis:
Right Arm □ Right Leg □
Left Arm □ Left Leg □
Bulbar □ Trunk □
Globulin Administered: Yes___ No____Date
15. Muscle Evaluation: Yes___ No___ Date_____________ Score_________________By Whom___________________________________________________
Death 
Date
16. Final Clinical Diagnosis; Poliomyelitis; Paralytic________ Non-paralytic________ Suspect
Not Polio: (specify)__________________________________________
17. Attending Physician
19. Poliomyelitis Vaccination: Yes_______ No
Injection: (1) Date_____________Site_
(2) Date______________Site_
(3) Date______________ Site_
20. Vaccinated at: Private Physician’s Office
Health Department Clinic_
School Clinic___________
Other___________________
PHS 400 .1 1 2  (CDC) GA.
REV. 5-55
18. Hospital
Mfr. Lot No.
Mfr. Lot No.
Mfr. Lot No.
21. Name of private physician or clinic and exact address;
Name_____________________________________________________
Address______________________________________City or Town
1. Patient Stool:
Specimen (1) Date Collected Lab. Sent to Date Sent
Specimen (2) Date Collected Lab. Sent to Date Sent
Specimen (3) Date Collected Lab. Sent to Date Sent
Patient Blood:
Acute Spec.(l)Date Collected Lab. Sent to Date Sent
Conval.Spec.(2)Date Collected Lab. Sent to Date Sent
Conval.Spec.(3)Date Collected Lab. Sent to Date Sent
a.
b.
c.
d.
e.
f.
g-
h.
i. 
j-
Name Age Sex
Vaccinated Illness* Date Stool 
Collected
Date Sent 
to Lab. Laboratory Sent toYes No Yes No
•(Defined as febrile illness at any time beginning two weeks prior to date patient named in Item 1 first felt unwell)
Name(s) of Informant(s) Relationship to Patient
Name of Investigator Title Date
Pertinent Remarks:
